1083224-23-0 | Heterocyclic Building Blocks-isoxazole

Simple exploration of 1083224-23-0

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Electric Literature of 1083224-23-0. In my other articles, you can also check out more blogs about 1083224-23-0

Electric Literature of 1083224-23-0, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 1083224-23-0, Name is 5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid, molecular formula is C10H5F2NO3. In a Patent，once mentioned of 1083224-23-0

Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.

Reference：
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Discovery of 1083224-23-0

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Recommanded Product: 1083224-23-0, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 1083224-23-0, in my other articles.

One of the major reasons for studying chemical kinetics is to use measurements of the macroscopic properties of a system, Recommanded Product: 1083224-23-0, such as the rate of change in the concentration of reactants or products with time.In a article, mentioned the application of 1083224-23-0, Name is 5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid, molecular formula is C10H5F2NO3

The application relates to crystalline forms of (3S,4S)-1- Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)- amide; processes for the preparation thereof, and pharmaceutical compositions containing such crystalline forms. The compound acts as CXCR7 receptor modulator and is thus useful for the treatment of cancer.

Reference：
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Brief introduction of 1083224-23-0

The synthetic route of 1083224-23-0 has been constantly updated, and we look forward to future research findings.

1083224-23-0, 5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,1083224-23-0

To a solution of rac-(3R*,4R*)-4-amino-3-methyl-piperidine-1 ,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (225 mg, 0.83 mmol) in DMF (5 mL) at RT is added 5-(2,4- difluorophenyl)isoxazole-3-carboxylic acid (205 mg, 0.91 mmol). DIPEA (0.283 mL, 1.65 mmol) is then added followed by HATU (346 mg, 0.91 mmol). The reaction mixture is stirred overnight at RT. The crude mixture is purified by prep. LC-MS in basic conditions. The title compound is obtained as a pale yellow solid. LC-MS method A: tR = 1.01 Min; [M+H]+ = 480.14.

The synthetic route of 1083224-23-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; IDORSIA PHARMACEUTICALS LTD; AISSAOUI, Hamed; GUERRY, Philippe; LEHEMBRE, Francois; POTHIER, Julien; POUZOL, Laetitia; RICHARD-BILDSTEIN, Sylvia; YUAN, Shuguang; (273 pag.)WO2018/19929; (2018); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

Analyzing the synthesis route of 1083224-23-0

The synthetic route of 1083224-23-0 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1083224-23-0,5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.,1083224-23-0

[0301] To a solution of 5 -(2, 4-difluorophenyl)isoxazole-3 -carboxylic acid (100 mg, 0.44 mmol, 1 equiv) in DMF (1 mL), were added HATU (185 mg, 0.48 mmol, 1.1 equiv). The mixture was treated drop wise with DIPEA (183 mg, 1.42 mmol, 3.2 equiv). After stirring at RT for 15 minutes, the mixture was treated drop wise with a solution of the l-(2,4- bis(trifluoromethyl)benzyl)-lH-pyrazol-4-amine (137 mg, 0.44 mmol, 1 equiv) in DMF (1 mL). The reaction mixture was kept under stirring for 24 hrs at RT. Product formation was confirmed with TLC & LCMS and reaction mixture was diluted EtOAc (50 mL) & washed with water (50 mL X 2). Organic layer dried over Na2S04 & concentrated under reduced pressure to obtain crude which was further purified by flash column chromatography to obtain pure product N-(l-(2,4-bis(trifluoromethyl)benzyl)-lH-pyrazol-4-yl)-5-(2,4- difluorophenyl)isoxazole-3-carboxamide. (36 mg, 15.7% as off white solid) ‘fl NMR (400 MHz, DMSO-c 6) d 11.16 (s, 1H), 8.33 (s, 1H), 8.10 (q, J= 8.3 Hz, 3H), 7.78 (s, 1H), 7.6l(t, J= 10.9 Hz, 1H), 7.35 (dd, J= 10.1, 7.7 Hz, 1H), 7.26 (d, J= 2.9 Hz, 1H), 7.06 (d, J= 8.1Hz, lH),5.67 (s, 2H).

The synthetic route of 1083224-23-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; PRAXIS BIOTECH LLC; ALFARO, Jennifer; BELMAR, Sebastian; NUNEZ VASQUEZ, Gonzalo Esteban; PUJALA, Brahmam; SATHE, Balaji Dashrath; BERNALES, Sebastian; CHAKRAVARTY, Sarvajit; THAKRAL, Pooja; PATIDAR, Rajesh Kumar; (344 pag.)WO2019/195810; (2019); A2;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

Analyzing the synthesis route of 1083224-23-0

1083224-23-0, The synthetic route of 1083224-23-0 has been constantly updated, and we look forward to future research findings.

General procedure: To a solution of rac-(3R*,4R*)-4-amino-1-benzyl-piperidine-3-carboxylic acid methyl ester (10.00 g, 33.4 mmol) in DMF (200 mL) is added 5-(2,4-difluorophenyl)isoxazole-3-carboxylic acid (7.74 g, 33.4 mmol). DIPEA (24.5 mL, 140 mmol) is then added followed by HATU (13.32 g, 35 mmol). The reaction mixture is stirred for 1 h. The reaction mixture is concentrated, diluted with DCM (750 mL) and treated with aq. sat. NaHC03 (600 mL). The organic layer is dried over MgS04 and evaporated. The crude residue is purified by prep. LC- MS in basic conditions to give the title compound; LC-MS method D tR = 1.14 min; [M+H]+ = 456.18.

1083224-23-0, The synthetic route of 1083224-23-0 has been constantly updated, and we look forward to future research findings.

Downstream synthetic route of 1083224-23-0

As the paragraph descriping shows that 1083224-23-0 is playing an increasingly important role.

1083224-23-0, 5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a solution of rac-(3R*,4R*)-4-amino-1-cyclohexyl-piperidine-3-carboxylic acid methyl ester 1.01 b (2.64 g, 10.4 mmol) in DMF (56.7 mL) at RT is added 5-(2,4-difluorophenyl)isoxazole- 3-carboxylic Acid (2.42 g, 10.4 mmol). DIPEA (5.83 mL, 33.4 mmol) is then added followed by HATU (4.16 g, 10.9 mmol). The reaction mixture is stirred overnight (17 h). The reaction mixture is concentrated, dissolved in DCM (300 mL) and treated with aq. sat. NaHC03 (225 mL). The organic layer is dried over MgS04 and evaporated. The crude residue is purified by prep. LC-MS under basic conditions (method E). The title compound is obtained as white powder; LC-MS method D tR = 1.15 min; [M+H]+ = 448.19., 1083224-23-0

As the paragraph descriping shows that 1083224-23-0 is playing an increasingly important role.

Simple exploration of 1083224-23-0

1083224-23-0, 1083224-23-0 5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid 28951583, aIsoxazoles compound, is more and more widely used in various.

1083224-23-0, 5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a solution of (3S,4S)-4-amino-piperidine-1 ,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (1 g, 3.87 mmol) in DMF (8 mL) at RT is added 5-(2,4-difluorophenyl)isoxazole-3- carboxylic acid (1.3 g, 5.81 mmol). DIPEA (2.12 mL, 12.4 mmol) is then added followed by HATU (1.55 g, 4.06 mmol). The reaction mixture is stirred overnight at RT. The reaction mixture is concentrated, dissolved in DCM (100 mL) and treated twice with aq. sat. NaHC03 (l OOmL). The organic layer is dried over MgS04 and evaporated. The crude residue is purified by flash chromatography over 40 g of silica gel with heptane/EtOAc system (1 :0 to 3:1 )as eluent to yield the title compound as white powder; LC-MS method A: tR = 0.94 min; [M+H]+ = 466.04. 1H NMR (400 MHz, CDCI3) <5: 7.23-7.36 (m, 1 H), 7.96 (m, 1 H), 6.96-7.12 (m, 3 H), 6.79-6.91 (m, 1 H), 4.29-4.51 (m, 2 H), 4.00-4.22 (m, 1 H), 3.64-3.78 (m, 3 H), 2.85- 3.09 (m, 2 H), 2.50-2.68 (m, 1 H), 2.10-2.27 (m, 1 H), 1.42-1.69 (m, 1 1 H), 1.21-1.38 (m, 1 H). 1083224-23-0, 1083224-23-0 5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid 28951583, aIsoxazoles compound, is more and more widely used in various.